Evidence map›Paper›PMID 41433110›Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2026

Natural History and Clinical Associations with Long-Term Outcomes in Primary C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative GN.

Giliane Nanchen, Maddalena Marasà, Matteo Breno, Carolina Martinatto, Miriam Rigoldi, Marina Noris, Elena Bresin, Sara Gamba, Laura Bottanelli, Zahra Imanifard and 33 more

Abstract read
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors.

Giliane NanchenClinical Research Center for Rare Diseases "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.ORCID 0000-0002-8522-7524
Maddalena MarasàClinical Research Center for Rare Diseases "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.ORCID 0000-0003-0712-2329
Matteo BrenoClinical Research Center for Rare Diseases "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Carolina MartinattoClinical Research Center for Rare Diseases "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Miriam RigoldiClinical Research Center for Rare Diseases "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.ORCID 0000-0001-5849-0418
Marina NorisClinical Research Center for Rare Diseases "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.ORCID 0000-0001-7651-5033
Elena BresinClinical Research Center for Rare Diseases "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.ORCID 0000-0003-4198-2891
Sara GambaClinical Research Center for Rare Diseases "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.ORCID 0000-0002-4887-890
Laura BottanelliClinical Research Center for Rare Diseases "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.ORCID 0009-0008-4942-242
Zahra ImanifardClinical Research Center for Rare Diseases "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.ORCID 0009-0001-0856-2556
Rossella PirasClinical Research Center for Rare Diseases "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.ORCID 0000-0002-0218-0901
Roberta DonadelliClinical Research Center for Rare Diseases "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Matias TrilliniClinical Research Center for Rare Diseases "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.ORCID 0000-0003-1859-1729
Francesco EmmaDivision of Nephrology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy.ORCID 0000-0002-0383-3468
Marina VivarelliLaboratory of Nephrology and Clinical Trial Center, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy.ORCID 0000-0002-2448-1959
Luca AntonucciDivision of Nephrology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy.ORCID 0000-0001-7662-079
Camillo CarraraClinical Research Center for Rare Diseases "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Piero RuggenentiClinical Research Center for Rare Diseases "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Gaetano La MannaNephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.ORCID 0000-0001-5473-8551
Giorgia ComaiNephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.ORCID 0000-0003-4160-8840
Enrico VidalPediatric Nephrology Dialysis and Transplant Unit, Department of Women's and Children's Health, Padua University Hospital, Padua, Italy.ORCID 0000-0003-3963-0803
Valeria SilecchiaPediatric Nephrology Dialysis and Transplant Unit, Department of Women's and Children's Health, Padua University Hospital, Padua, Italy.
Andrea PasiniPediatric Nephrology and Dialysis Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Andrea RanghinoUnit of Nephrology, Dialysis and Transplantation, Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy.
Alessandra CingolaniUnit of Nephrology, Dialysis and Transplantation, Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy.ORCID 0000-0001-9838-8936
Gabriele DonatiUOC of Nephrology, Dialysis and Transplantation, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.ORCID 0000-0001-8549-1221
Silvia GiovanellaDipartimento CHIMOMO, Università di Modena e Reggio Emilia, Modena, Italy.ORCID 0000-0003-1298-5508
Luigi BianconeDivision of Nephrology Dialysis and Transplantation, Department of Medical Sciences, Città Della Salute e Della Scienza Hospital, University of Turin, Turin, Italy.ORCID 0000-0002-7700-6350
Laura ValenzaDivision of Nephrology Dialysis and Transplantation, Department of Medical Sciences, Città Della Salute e Della Scienza Hospital, University of Turin, Turin, Italy.
Enrico VerrinaUnit of Nephrology, Dialysis and Transplantation, IRCCS Istituto Giannina Gaslini, Genova, Italy.ORCID 0000-0002-5178-1949
Andrea AngelettiUnit of Nephrology, Dialysis and Transplantation, IRCCS Istituto Giannina Gaslini, Genova, Italy.ORCID 0000-0002-6121-5326
Giuliano BrunoriUOC Nephrology and Dialysis, Azienda Provinciale per i Servizi Sanitari, APSS, Ospedale Santa Chiara, and CISMed, University of Trento, Trento, Italy.
Laura SottiniUOC Nephrology and Dialysis, Azienda Provinciale per i Servizi Sanitari, APSS, Ospedale Santa Chiara, and CISMed, University of Trento, Trento, Italy.
Mario GiordanoUnit of Pediatric Nephrology and Dialysis, Azienda Ospedaliero-Universitaria Policlinico Consorziale Giovanni XXIII, Bari, Italy.ORCID 0000-0003-4224-636
Diletta Domenica TorresUnit of Pediatric Nephrology and Dialysis, Azienda Ospedaliero-Universitaria Policlinico Consorziale Giovanni XXIII, Bari, Italy.
Federico AlbericiNephrology Unit, Università degli Studi di Brescia - ASST Spedali Civili di Brescia, Brescia, Italy.ORCID 0000-0002-1686-5709
Federica MesciaNephrology Unit, Università degli Studi di Brescia - ASST Spedali Civili di Brescia, Brescia, Italy.ORCID 0000-0002-2759-4027
Umberto MaggioreUnit of Nephrology, Dipartimento di Medicina e Chirurgia, Azienda Ospedaliera Universitaria di Parma, Università di Parma, Parma, Italy.ORCID 0000-0002-7468-9600
Micaela GentileUnit of Nephrology, Dipartimento di Medicina e Chirurgia, Azienda Ospedaliera Universitaria di Parma, Università di Parma, Parma, Italy.
Ariela BenigniClinical Research Center for Rare Diseases "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Giuseppe RemuzziClinical Research Center for Rare Diseases "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.ORCID 0000-0002-6194-3446
Erica DainaClinical Research Center for Rare Diseases "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.ORCID 0000-0002-2419-5493
Italian Registry of MPGN

Funding

Fondazione per la Ricerca Biomedica Project ERAPERMED2020-151, GA 779282Ministero della Salute Project COMPRare EJP RD JTC-2022
6 · The paper itself

Abstract

key pointsThis retrospective study analyzed clinical, histological, and biochemical data from a large cohort of participants with biopsy-proven primary C3 glomerulopathy/immune complex-mediated membranoproliferative GN. C3 glomerulopathy and immune complex-mediated membranoproliferative GN subjects shared most baseline and longitudinal features; 10-year kidney survival did not differ across histological subtypes. Older age at onset and higher proteinuria levels at 1 year from biopsy were the strongest predictors of kidney failure.

backgroundMembranoproliferative glomerulonephritides (MPGNs) are defined by a typical glomerular histopathological pattern including C3 glomerulopathy (C3G) and immune complex-mediated MPGN (IC-MPGN). The overall prognosis is poor and the treatment options remain limited. Outcome predictors and reliable surrogate endpoints are critically needed for interventional trials. Herein, we described the natural history and analyzed clinical, histological and biochemical data from a large cohort of patients with primary C3G/IC-MPGN.

methodsThis is a retrospective analysis of patients with biopsy-proven primary C3G or IC-MPGN from the Italian Registry of MPGN. Demographic, clinical and histopathological data, molecular complement profiles, treatment patterns, and outcomes were collected. We performed univariable and multivariable Cox regressions and Kaplan-Meier survival analyses to assess risk associations with kidney disease progression. The composite endpoint included ESKD (defined by either eGFR <15 ml/min per 1.73 m 2 , initiation of chronic dialysis or kidney transplantation), doubling of serum creatinine at the last available follow-up, or death by kidney-related causes.

resultsOf the 349 patients identified, 208 had C3G and 141 IC-MPGN. Females were 41%, and over half were younger than 18 years old at time of biopsy. C3G and IC-MPGN patients shared most baseline and longitudinal features, with IC-MPGN patients presenting with higher baseline proteinuria (median 4.0 versus 2.3 g/24 hours, P < 0.001). Median eGFR at presentation was 83 ml/min per 1.73 m 2 . Twenty-six percent of patients progressed to ESKD over a median follow-up of 5 years from diagnosis. Higher proteinuria levels at 1 year from biopsy, particularly ≥1 g/24 hours, were significantly associated with a higher risk of adverse kidney outcomes. Pediatric onset was associated with better kidney survival, whereas kidney survival at 10 years did not statistically differ across histological subtypes. Complement dysregulation and rare functional variants in complement genes were not associated with outcomes.

conclusionsOur findings from a large and well-characterized cohort of individuals with primary C3G/IC-MPGN identify age at onset and proteinuria levels as associations with kidney survival, a finding that should inform future interventional trials.

Indexed as

Antigen-Antibody ComplexComplement C3Glomerulonephritis, MembranoproliferativeAdultBiopsyDisease ProgressionFemaleHumansKidney Failure, ChronicKidney TransplantationMaleMiddle AgedPrognosisProteinuriaRegistriesRetrospective StudiesAntigen-Antibody ComplexC3 protein, humanComplement C3complementepidemiology and outcomesESKDglomerular diseaseglomerulopathyGNlongitudinal data analysisMPGN (membranoproliferative GN)proteinuria

Identifiers

PMID41433110
PMCPMC13065177

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.